Meza-Junco Judith, Sawyer Michael B
Department of Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
Biologics. 2012;6:137-46. doi: 10.2147/BTT.S23917. Epub 2012 Jun 20.
Gastric cancer (GC) is currently the second leading cause of cancer death worldwide; unfortunately, most patients will present with locally advanced or metastatic disease. Despite recent progress in diagnosis, surgery, chemotherapy, and radiotherapy, prognosis remains poor. A better understanding of GC biology and signaling pathways is expected to improve GC therapy, and the integration of targeted therapies has recently become possible and appears to be promising. This article focuses on anti-Her-2 therapy, specifically trastuzumab, as well as other epidermal growth factor receptor antagonists such as cetuximab, panitumub, matuzumab, nimotzumab, gefitinib, and erlotinib. Additionally, drugs that target angiogenesis pathways are also under investigation, particulary bevacizumab, ramucirumab, sorafenib, sunitinib, and cediranib. Other targeted agents in preclinical or early clinical development include mTOR inhibitors, anti c-MET, polo-like kinase 1 inhibitors, anti-insulin-like growth factor, anti-heat shock proteins, and small molecules targeting Hedgehog signaling.
胃癌（GC）是目前全球癌症死亡的第二大主要原因；不幸的是，大多数患者就诊时已处于局部晚期或转移性疾病阶段。尽管最近在诊断、手术、化疗和放疗方面取得了进展，但预后仍然很差。更好地了解胃癌生物学和信号通路有望改善胃癌治疗，并且靶向治疗的整合最近已成为可能且似乎很有前景。本文重点关注抗Her-2治疗，特别是曲妥珠单抗，以及其他表皮生长因子受体拮抗剂，如西妥昔单抗、帕尼单抗、美妥珠单抗、尼妥珠单抗、吉非替尼和厄洛替尼。此外，针对血管生成途径的药物也在研究中，特别是贝伐单抗、雷莫西尤单抗、索拉非尼、舒尼替尼和西地尼布。其他处于临床前或早期临床开发阶段的靶向药物包括mTOR抑制剂、抗c-MET、polo样激酶1抑制剂、抗胰岛素样生长因子、抗热休克蛋白以及靶向Hedgehog信号的小分子。
